United States - English - NLM (National Library of Medicine)

hanul trading co., ltd. - levomenthol (unii: bz1r15mtk7) (levomenthol - unii:bz1r15mtk7), camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et), diphenhydramine (unii: 8gts82s83m) (diphenhydramine - unii:8gts82s83m), .alpha.-tocopherol, dl- (unii: 7qwa1rio01) (.alpha.-tocopherol, dl- - unii:7qwa1rio01), methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz), peppermint oil (unii: av092ku4jh) (peppermint - unii:v95r5kmy2b), nonivamide (unii: s846b891or) (nonivamide - unii:s846b891or) - levomenthol 2.769 mg in 0.2832 g - [purpose] topical analgesic [indications] anti-inflammatory effect to following symptoms: bruise, wrick, muscle pain, arthralgia, backache, shoulder pain, neuralgia, and rheumatic pain.

United States - English - NLM (National Library of Medicine)

zoetis inc. - tulathromycin (unii: q839i13422) (tulathromycin - unii:q839i13422), ketoprofen (unii: 90y4qc304k) (ketoprofen - unii:90y4qc304k) - draxxin® kp is indicated for the treatment of bovine respiratory disease (brd) associated with mannheimia haemolytica , pasteurella multocida , histophilus somni , and mycoplasma bovis , and control of pyrexia associated with brd in beef steers, beef heifers, beef calves 2 months of age and older, beef bulls, dairy bulls, and replacement dairy heifers. not for use in reproducing animals over one year of age, dairy calves, or veal calves. the use of draxxin kp injection is contraindicated in animals previously found to be hypersensitive to tulathromycin and ketoprofen. not for human use. keep out of reach of children. the safety data sheet (sds) provides more detailed occupational safety information. to obtain a safety data sheet contact zoetis inc. at 1-888-963-8471.

Australia - English - Department of Health (Therapeutic Goods Administration)

natus medical pty ltd - 46566 - neurophysiologic monitoring system - to be used as an electrophysiology recording device via external recording electrodes attached to the patient's skin

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - caspofungin acetate, quantity: 77.7 mg (equivalent: caspofungin, qty mg) - injection, powder for - excipient ingredients: mannitol; sucrose; sodium hydroxide; hydrochloric acid - caspofungin kp is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - caspofungin acetate, quantity: 55.5 mg (equivalent: caspofungin, qty 50 mg) - injection, powder for - excipient ingredients: sodium hydroxide; mannitol; sucrose; hydrochloric acid - caspofungin kp is indicated for:,? empirical therapy for presumed fungal infections in febrile, neutropenic patients whose fever has failed to respond to broad-spectrum antibiotics,? treatment of:,-invasive candidiasis, including candidaemia,-oesophageal candidiasis,-invasive aspergillosis in patients who are refractory to or intolerant of other therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - calcitriol, quantity: 0.25 microgram - capsule, soft - excipient ingredients: fractionated coconut oil; butylated hydroxyanisole; butylated hydroxytoluene; gelatin; glycerol; sorbitol solution (70 per cent) (non-crystallising); purified water; iron oxide red; iron oxide yellow; titanium dioxide - calcitriol kp is indicated for the treatment of established osteoporosis diagnosed by objective measuring techniques, such as densitometry, or by radiographic evidence of atraumatic fracture.,calcitriol kp is also indicated for the prevention of corticosteroid-induced osteoporosis in patients commencing oral steroid therapy in a dose and regimen expected to result in a significant bone loss.,calcitriol kp is indicated in the treatment of hypocalcemia in patients with uremic osteodystrophy, hypoparathyroidism and in hypophosphataemic rickets.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ezetimibe, quantity: 10 mg - tablet, uncoated - excipient ingredients: povidone; lactose monohydrate; sodium lauryl sulfate; magnesium stearate; croscarmellose sodium - adults (? 18 years),primary hypercholesterolaemia ezetimibe kp administered alone, or with an hmg-coa reductase inhibitor (statin), is indicated as adjunctive therapy to diet in patients with primary (heterozygous familial and non-familial) hypercholesterolaemia.,homozygous familial hypercholesterolaemia (hofh) ezetimibe kp, administered with a statin, is indicated for patients with hofh. patients may also receive adjunctive treatments (e.g., ldl apheresis).,homozygous sitosterolaemia (phytosterolaemia) ezetimibe kp is indicated for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolaemia.,prevention of cardiovascular disease ezetimibe kp, is indicated for administration in combination with the maximum tolerated dose of a statin with proven cardiovascular benefit in patients with coronary heart disease (chd) and a history of acute coronary syndrome (acs) in need of additional lowering of ldl-c in the expectation of a modest further reduction in the risk of cardiovascular events following at least one year of therapy (see clinical trials).,children and adolescents 10-17 years (pubertal status: boys tanner stage ii and above and girls who are at least one year post menarche),heterozygous familial hypercholesterolaemia (hefh) ezetimibe kp co-administered with simvastatin (doses up to 40 mg) is indicated as an adjunctive therapy to diet in adolescent patients (10-17 years old) with heterozygous familial hypercholesterolaemia where use of a combination product is appropriate: ? patients not appropriately controlled with a statin or ezetimibe alone ? patients already treated with a statin and ezetimibe,homozygous familial hypercholesterolaemia (hofh) ezetimibe kp co-administered with simvastatin (doses up to 40 mg) is indicated in adolescent patients (10-17 years old) with hofh. patients may also receive adjunctive treatments (e.g. ldl apheresis)

India - English - Central Drugs Standard Control Organization

vhb - cardioplegia - inj - 2 amp

India - English - Central Drugs Standard Control Organization

vhb - cardioplegia - amp - mg 3.25g,k 1.19g,procaine 272.8mg;20ml - 2x20ml

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

paracetamol 120mg/5ml